JCR Pharmaceuticals Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on JCR Pharmaceuticals Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how JCR Pharmaceuticals Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with JCR Pharmaceuticals Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
JCR Pharmaceuticals Co Ltd (JCR Pharma) is a biopharmaceutical company. It produces, purchases, and sells medical drugs, pharmaceutical raw materials and regenerative medicine products. The company's product portfolio includes Growject for growth hormone deficiency and short stature; Izcargo for Mucopolysaccharidosis type II; Agalsidase Beta BS IV Infusion for Fabry disease; Temcell HS Injection for acute graft-versus-host disease; and Epoetin and Darbepoetin Alfa BS injections for managing renal anemia. Its R&D pipeline focuses on advanced therapeutic solutions using its proprietary J-Brain Cargo and J-MIG System technologies. JCR Pharma is headquartered in Ashiya-Shi, Hyogo, Japan.
Headquarters
Japan
Address
3-19, Kasuga-Cho, Ashiya, Hyogo, 659-0021
Website
www.jcrpharm.co.jp
Telephone
81 797 328591
No of Employees
985
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4552 (TYO)
Revenue (2025)
$259.1M
21.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
145.8%
(2025 vs 2024)
Market Cap*
$379.2M
Net Profit Margin (2025)
XYZ
137.5%
(2025 vs 2024)
* As of and is in US$
JCR Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Growject: Growth Hormone Deficiency | Growject |
| Izcargo: Mucopolysaccharidosis Type 2 | Izcargo |
| Agalsidase Beta BS IV Infusion: Fabry Disease | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In July, the company signed a license agreement with Alexion to utilize its proprietary JUST-AAV capsids for developing genomic medicines. |
| 2025 | Others | In July, the company was selected for the Ministry of Economy, Trade and Industry’s Regenerative CDMO Subsidy to enhance biomanufacturing for regenerative and gene therapies. |
| 2025 | New Products/Services | In June, the company introduced its new website, www.jcrpharm.com. |
Competitor Comparison
| Key Parameters | JCR Pharmaceuticals Co Ltd | Takeda Pharmaceutical Co Ltd | Zeria Pharmaceutical Co Ltd | Sinphar Pharmaceutical Co Ltd | OrphanPacific Inc |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Taiwan | Japan |
| City | Ashiya | Chuo-Ku | Chuo-Ku | Dongshan | Minato |
| State/Province | Hyogo | Tokyo | Tokyo | - | Tokyo |
| No. of Employees | 985 | 47,029 | 1,748 | 984 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Toru Ashida | Director; Chairman | Executive Board | 2026 | 58 |
| Hiroyuki Sonoda, Ph.D. | Chief Scientific Officer; Director; President | Executive Board | 2026 | 48 |
| Yoshio Hiyama, Ph.D. | Managing Executive Officer-Quality Assurance; Executive Director-Quality Assurance Division; Director | Executive Board | 2024 | 66 |
| Andrea Spezzi, M.D. | Managing Executive Officer-Development Division; Director | Executive Board | 2024 | 61 |
| Shin Ashida | Director | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer